Health Care Innovation
Commentary
Under Dems’ Drug Pricing Plan, Dozens of New Meds Will Never Be Invented
The Congressional Budget Office just released an analysis of House Democrats’ effort to impose price controls on prescription drugs, H.R. 3 — the Elijah E. Cummings Lower Drug Costs Now Act. The CBO’s chief finding is grim. By drastically limiting pharmaceutical revenue, H.R. 3 would starve scientists of the funding they need ...
Drug Pricing
Watch Wayne Winegarden Discuss Drug Pricing Reform with Scripps National News
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value drugs with Scripps National News. The report aired on 60 television stations in 42 markets across the ...
Commentary
Let’s Not Repeat Canada’s Healthcare Mistakes
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Commentary
Democrats $3.5 Trillion Budget Leaves the Health Care Sector as Broken as Ever
One of the most striking aspects of the $3.5 trillion budget resolution proposed last week by Senate Democrats is how little it does to improve America’s ailing healthcare system. The plan funnels massive sums of money into everything from Medicare and Medicaid to Obamacare’s premium tax credits. But it utterly fails to ...
Drug Pricing
Watch PRI, Pioneer Institute Webinar on ICER, health care innovation
The Pioneer Institute and Pacific Research Institute hosted an educational webinar on the importance of protecting treatment access, innovation, and equity as Washington addresses drug pricing reforms on July 19, 2021. Pioneer Institute, PRI, and special guests explored the current policy landscape on treatment value and access and how policy ...
Commentary
America’s drug rebate system is broken
Rebates and discounts are generally viewed as important competitive tools that lower prices for consumers, and rightly so. But consumers should beware when discounts create competitive restrictions that reduces their choices and increases their costs. Such is the case when dominant drug manufacturers use rebates to keep lower-priced drugs off ...
Featured
Read Sally Pipes’ Remarks from Adam Smith Society National Meeting
Below are remarks delivered by PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes at the annual national meeting of the Adam Smith Society on June 9, 2021. She spoke about free market health care solutions. Thank you so very much for inviting me ...
Blog
To See the Fallacy of H.R. 3 (Lower Drug Costs Now Act) Just Look at the Inflation Data
Railing about sky high drug prices makes good political theater and helps drum up support for the latest attempt to impose drug price controls (H.R. 3 or the Lower Drug Costs Now Act). This accusation also perpetuates misinformation. If implemented, H.R. 3 would endanger patient access to current efficacious medicines ...
Commentary
Biden’s Intellectual Property Waiver Puts Political Symbolism Before Saving Lives
President Biden recently backed a World Trade Organization proposal to waive intellectual property protections on COVID-19 vaccines and therapies — a move the Trump administration rejected just a few months ago. The White House’s decision is a catastrophe. The waiver will do nothing to increase access to vaccines. It will, however, undermine the system ...
Commentary
With HR 3, House Democrats Lose Their Grip on Reality
Last week, House Democrats introduced H.R. 3, a bill that would empower the federal government to set prescription drug prices for the entire U.S. pharmaceutical market. The measure comes at the worst possible time. The rapid development of effective vaccines against COVID-19 has demonstrated what can happen when the drug industry ...
Under Dems’ Drug Pricing Plan, Dozens of New Meds Will Never Be Invented
The Congressional Budget Office just released an analysis of House Democrats’ effort to impose price controls on prescription drugs, H.R. 3 — the Elijah E. Cummings Lower Drug Costs Now Act. The CBO’s chief finding is grim. By drastically limiting pharmaceutical revenue, H.R. 3 would starve scientists of the funding they need ...
Watch Wayne Winegarden Discuss Drug Pricing Reform with Scripps National News
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value drugs with Scripps National News. The report aired on 60 television stations in 42 markets across the ...
Let’s Not Repeat Canada’s Healthcare Mistakes
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Democrats $3.5 Trillion Budget Leaves the Health Care Sector as Broken as Ever
One of the most striking aspects of the $3.5 trillion budget resolution proposed last week by Senate Democrats is how little it does to improve America’s ailing healthcare system. The plan funnels massive sums of money into everything from Medicare and Medicaid to Obamacare’s premium tax credits. But it utterly fails to ...
Watch PRI, Pioneer Institute Webinar on ICER, health care innovation
The Pioneer Institute and Pacific Research Institute hosted an educational webinar on the importance of protecting treatment access, innovation, and equity as Washington addresses drug pricing reforms on July 19, 2021. Pioneer Institute, PRI, and special guests explored the current policy landscape on treatment value and access and how policy ...
America’s drug rebate system is broken
Rebates and discounts are generally viewed as important competitive tools that lower prices for consumers, and rightly so. But consumers should beware when discounts create competitive restrictions that reduces their choices and increases their costs. Such is the case when dominant drug manufacturers use rebates to keep lower-priced drugs off ...
Read Sally Pipes’ Remarks from Adam Smith Society National Meeting
Below are remarks delivered by PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes at the annual national meeting of the Adam Smith Society on June 9, 2021. She spoke about free market health care solutions. Thank you so very much for inviting me ...
To See the Fallacy of H.R. 3 (Lower Drug Costs Now Act) Just Look at the Inflation Data
Railing about sky high drug prices makes good political theater and helps drum up support for the latest attempt to impose drug price controls (H.R. 3 or the Lower Drug Costs Now Act). This accusation also perpetuates misinformation. If implemented, H.R. 3 would endanger patient access to current efficacious medicines ...
Biden’s Intellectual Property Waiver Puts Political Symbolism Before Saving Lives
President Biden recently backed a World Trade Organization proposal to waive intellectual property protections on COVID-19 vaccines and therapies — a move the Trump administration rejected just a few months ago. The White House’s decision is a catastrophe. The waiver will do nothing to increase access to vaccines. It will, however, undermine the system ...
With HR 3, House Democrats Lose Their Grip on Reality
Last week, House Democrats introduced H.R. 3, a bill that would empower the federal government to set prescription drug prices for the entire U.S. pharmaceutical market. The measure comes at the worst possible time. The rapid development of effective vaccines against COVID-19 has demonstrated what can happen when the drug industry ...
